Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saikosaponin A is a triterpene saponin and one of the main bioactive constituents isolated from the roots of *Bupleurum chinense* (Radix Bupleuri), a traditional medicinal plant widely used in East Asia. It consists of an oleanane-type triterpenoid aglycone linked to carbohydrate moieties[1][2][6]. Pharmacologically, saikosaponin A exhibits diverse biological activities including anti-inflammatory, neuroprotective (notably anticonvulsant and antidepressant), hepatoprotective, immunomodulatory, antiviral and antitumor effects[2][7][9]. Mechanistically, it modulates multiple signaling pathways such as PI3K/Akt/mTOR, MAPK/ERK, JAK/STAT and NF-kB; inhibits N-methyl-D-aspartic acid receptor currents; enhances monoamine neurotransmitter levels; suppresses hippocampal inflammation; reduces oxidative stress; regulates apoptosis-related proteins (e.g., Bcl‑2 family); and influences gut microbiota composition[2][7][9]. Its broad activity profile has made it an object of interest for research into central nervous system disorders (including epilepsy and depression), liver diseases and inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on saikosaponin a.